Please assess the completion status of the following clinical trial:

Trial Title: Radiotherapy Alone Versus Concurrent Chemoradiation in Low Risk NK/T-cell Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age range 18-75 years old~* Histological confirmed, previously untreated stage IE nasal NK/T cell lymphoma without following risk factors including local invasion, B symptoms and high LDH level~* ECOG performance status 0-1~* Life expectancy of more than 3 months~* Adequate bone marrow and organ functions~Exclusion Criteria:~* non-nasal NK/T-cell lymphoma~* Prior exposure of methotrexate~* With third space effusion~* Pregnant or lactating women~* Serious uncontrolled diseases and intercurrent infection~* History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Radiotherapy alone (Type: ACTIVE_COMPARATOR): Radiotherapy alone Technique: IMRT Total Dose: 50 Gy Per fraction: 2 Gy
- Concurrent chemoradiation (Type: EXPERIMENTAL): Concurrent chemoradiation~Chemotherapy:~Methotrexate 40 mg/m2 weekly X 5 Radiotherapy Technique: IMRT Total dose: 50 Gy Per Fraction: 2 Gy

Based on this trial design, predict the completion outcome and termination type (if applicable).